Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 344

1.

Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.

Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, Willis F, Burny A, Lagneaux L, Bron D, Chatelain B, Chatelain C, Willems L.

Br J Haematol. 2009 Jan;144(1):41-52. doi: 10.1111/j.1365-2141.2008.07426.x. Epub 2008 Nov 1.

PMID:
19006566
2.

Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.

Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D.

Exp Hematol. 2007 Oct;35(10):1527-37. Epub 2007 Aug 13.

PMID:
17697742
3.

Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.

Yoon JY, Ishdorj G, Graham BA, Johnston JB, Gibson SB.

Apoptosis. 2014 Jan;19(1):191-200. doi: 10.1007/s10495-013-0906-7.

PMID:
24057147
4.

The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.

Pettitt AR, Sherrington PD, Cawley JC.

Br J Haematol. 1999 Sep;106(4):1049-51.

PMID:
10520012
6.

In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.

Duechler M, Linke A, Cebula B, Shehata M, Schwarzmeier JD, Robak T, Smolewski P.

Eur J Haematol. 2005 May;74(5):407-17.

PMID:
15813915
7.

The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.

McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, Williams DC, Zisterer DM, Lawler M.

Cancer Res. 2009 Nov 1;69(21):8366-75. doi: 10.1158/0008-5472.CAN-09-0131. Epub 2009 Oct 13.

8.
9.

Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.

Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S, Dmoszynska A.

Ann Hematol. 2011 Feb;90(2):173-83. doi: 10.1007/s00277-010-1045-7. Epub 2010 Aug 17.

11.

Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.

Pettitt AR, Sherrington PD, Cawley JC.

Cancer Res. 2000 Aug 1;60(15):4187-93.

12.

Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.

Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, Lagneaux L.

Leukemia. 2009 Dec;23(12):2281-9. doi: 10.1038/leu.2009.176. Epub 2009 Aug 27.

PMID:
19710697
13.
14.
15.

Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.

de Viron E, Knoops L, Connerotte T, Smal C, Michaux L, Saussoy P, Vannuffel P, Beert E, Vekemans MC, Hermans C, Bontemps F, Van Den Neste E.

Br J Haematol. 2009 Dec;147(5):641-52. doi: 10.1111/j.1365-2141.2009.07900.x. Epub 2009 Sep 18.

PMID:
19764992
16.

In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues--correlation with clinical course.

Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA.

Leukemia. 1998 Aug;12(8):1230-5.

PMID:
9697877
17.

Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells.

Tosi P, Zinzani PL, Pellacani A, Ottaviani E, Magagnoli M, Tura S.

Leuk Lymphoma. 1997 Jul;26(3-4):343-8.

PMID:
9322897
18.

Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.

de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marco J, Silva A, Garcia-Pardo A.

J Leukoc Biol. 2002 Mar;71(3):495-502.

PMID:
11867687
19.

The triterpenoid CDDO induces apoptosis in refractory CLL B cells.

Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC.

Blood. 2002 Oct 15;100(8):2965-72.

20.

Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.

Mohammad RM, Limvarapuss C, Hamdy N, Dutcher BS, Beck FW, Wall NR, Al-Katib AM.

Int J Oncol. 1999 May;14(5):945-50.

PMID:
10200346

Supplemental Content

Support Center